ICER Report on Treatments for High Cholesterol – FH Foundation to Comment at Public Meeting February 5

The Institute for Clinical and Economic Review (ICER) - an organization that produces reports that analyze the cost effectiveness of drugs and other medical services - has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have both established atherosclerotic cardiovascular disease (ASCVD) and either Familial Hypercholesterolemia (FH) or who can't take statins due to side effects, recognizing the increased risk for further cardiovascular events for people with ASCVD and FH. The ICER report also recognized that individuals with FH are at higher risk for cardiovascular events earlier in life and the need for additional treatment options to improve outcomes for higher-risk individuals.

ICER will hold a public meeting on February 5 to review evidence included in its recent report on therapies for high cholesterol, to hear from stakeholders, consider the comparative clinical effectiveness of treatments, other potential benefits, and long-term "value for money." The FH Foundation's Founder and CEO Katherine Wilemon will offer public comments at the meeting, and VP of Policy and Outreach, Cat Davis Ahmed, will serve as a Patient Representative on the meeting's Policy Roundtable. This virtual meeting is open to the public. Register here if you are interested to attend.

Leave a Reply